|
|
Vaccine Detail
|
UV1 Telomerase Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: UV1 Telomerase Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007170
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TERT
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The therapeutic hTERT vaccine (UV1) consisting of three hTERT peptides representing the epitopes most frequently recognized by the long-term cancer survivors. GM-CSF is administered intradermally 10-15 minutes before the administration of UV1 (Lilleby et al., 2017).
- Description: This is for Prostate Cancer (NCT01784913). A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation (Lilleby et al., 2017; NCIT_C104747).
|
| Host Response |
|
|
| References |
Lilleby et al., 2017: Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer immunology, immunotherapy : CII. 2017; 66(7); 891-901. [PubMed: 28391357].
NCIT_C104747: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104747]
NCT01784913: [https://clinicaltrials.gov/show/NCT01784913/]
|
|
